Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
Andrew X. Zhu, Ryan David Nipp, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Jean-Frédéric Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia C. Girvan, Jonathon Gable, Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open, 5(4), pp. e000797-e000797, DOI: 10.1136/esmoopen-2020-000797.
